Patents Assigned to GenPharm International, Inc.
  • Publication number: 20130039850
    Abstract: The invention relates to transgenic non-human animals capable of producing high affinity human sequence antibodies. The invention is also directed to human sequence antibodies specific for human antigens, such as, human CD4. The invention is also directed to methods for producing human sequence antibodies.
    Type: Application
    Filed: July 9, 2012
    Publication date: February 14, 2013
    Applicant: GENPHARM INTERNATIONAL, INC.
    Inventors: Nils LONBERG, Robert M. KAY, Dianne M. FISHWILD
  • Patent number: 8231877
    Abstract: The invention relates to transgenic non-human animals capable of producing high affinity human sequence antibodies. The invention is also directed to human sequence antibodies specific for human antigens , such as, human CD4. The invention also is directed to methods for producing human sequence antibodies.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: July 31, 2012
    Assignee: GenPharm International, Inc.
    Inventors: Nils Lonberg, Robert M. Kay, Dianne M. Fishwild
  • Patent number: 7722873
    Abstract: The invention relates to transgenic non-human animals capable of producing high affinity human sequence antibodies. The invention is also directed to human sequence antibodies specific for human antigens, such as, human CD4. The invention also is directed to methods for producing human sequence antibodies.
    Type: Grant
    Filed: February 8, 2006
    Date of Patent: May 25, 2010
    Assignee: Genpharm International, Inc.
    Inventors: Nils Lonberg, Robert M. Kay, Dianne M. Fishwild
  • Patent number: 7084260
    Abstract: The invention relates to transgenic non-human animals capable of producing high affinity human sequence antibodies. The invention is also directed to human sequence antibodies specific for human antigens, such as, human CD4. The invention also is directed to methods for producing human sequence antibodies.
    Type: Grant
    Filed: October 10, 1996
    Date of Patent: August 1, 2006
    Assignee: GenPharm International, Inc.
    Inventors: Nils Lonberg, Robert M. Kay, Dianne M. Fishwild
  • Patent number: 7041871
    Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: May 9, 2006
    Assignee: GenPharm International, Inc.
    Inventors: Nils Lonberg, Robert M. Kay
  • Publication number: 20060026703
    Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.
    Type: Application
    Filed: December 10, 2004
    Publication date: February 2, 2006
    Applicant: GenPharm International, Inc.
    Inventors: Nils Lonberg, Robert Kay
  • Publication number: 20060015957
    Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.
    Type: Application
    Filed: December 10, 2004
    Publication date: January 19, 2006
    Applicant: GenPharm International, Inc.
    Inventors: Nils Lonberg, Robert Kay
  • Publication number: 20060015949
    Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.
    Type: Application
    Filed: December 10, 2004
    Publication date: January 19, 2006
    Applicant: GenPharm International, Inc.
    Inventors: Nils Lonberg, Robert Kay
  • Patent number: 6794132
    Abstract: The invention uses the power of display selection methods to screen libraries of human immunoglobulin genes from nonhuman transgenic animals expresing human immunoglobulins. Such screening produces unlimited numbers of high affinity human antibodies to any target of interest.
    Type: Grant
    Filed: December 1, 1999
    Date of Patent: September 21, 2004
    Assignees: Biosite, Inc., GenPharm International, Inc.
    Inventors: Joe Buechler, Gunars Valkirs, Jeff Gray, Nils Lonberg
  • Publication number: 20040107452
    Abstract: The present invention provides novel methods for modifying the genome of an animal cell which typically comprise the steps of: constructing a DNA molecule in which desired sequence modifications are contained in a segment of DNA (a “targeting DNA”) that is substantially isogenic with a DNA in the cell genome (a “target DNA”); introducing the targeting DNA construct into the cell (e.g., by microinjection, electroporation, transfection, or calcium phosphate precipitation); and selecting cells in which the desired sequence modifications have been introduced into the genome via homologous recombination.
    Type: Application
    Filed: November 24, 2003
    Publication date: June 3, 2004
    Applicant: GENPHARM INTERNATIONAL, INC.
    Inventors: Anton Berns, Els Robanus Maandag, Hein Te Riele
  • Patent number: 6653113
    Abstract: The present invention provides novel methods for modifying the genome of an animal cell which typically comprise the steps of: constructing a DNA molecule in which desired sequence modifications are contained in a segment of DNA (a “targeting DNA”) that is substantially isogenic with a DNA in the cell genome (a “target DNA”); introducing the targeting DNA construct into the cell (e.g., by microinjection, electroporation, transfection, or calcium phosphate precipitation); and selecting cells in which the desired sequence modifications have been introduced into the genome via homologous recombination.
    Type: Grant
    Filed: February 19, 1999
    Date of Patent: November 25, 2003
    Assignee: Genpharm International, Inc.
    Inventors: Anton Berns, Els Robanus Maandag, Hein te Riele
  • Patent number: 5877397
    Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and transgenic non-human animals having inactivated endogenous immunoglobulin genes. In one aspect of the invention, endogenous immunoglobulin genes are suppressed by antisense polynucleotides and/or by antiserum directed against endogenous immunoglobulins. Heterologous antibodies are encoded by immunoglobulin genes not normally found in the genome of that species of non-human animal. In one aspect of the invention, one or more transgenes containing sequences of unrearranged heterologous human immunoglobulin heavy chains are introduced into a non-human animal thereby forming a transgenic animal capable of functionally rearranging transgenic immunoglobulin sequences and producing a repertoire of antibodies of various isotypes encoded by human immunoglobulin genes. Such heterologous human antibodies are produced in B-cells which are thereafter immortalized, e.g.
    Type: Grant
    Filed: September 19, 1994
    Date of Patent: March 2, 1999
    Assignee: GenPharm International Inc.
    Inventors: Nils Lonberg, Robert M. Kay
  • Patent number: 5874299
    Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies, i.e., antibodies encoded by immunoglobulin heavy and light chain genes not normally found in the genome of that species of non-human animal. In one aspect of the invention, transgenes encoding unrearranged heterologous human immunoglobulin heavy and light chains are introduced into a non-human animal thereby forming a transgenic animal capable of producing antibodies encoded by human immunoglobulin genes. Such heterologous human antibodies are produced in B-cells which are thereafter immortalized, e.g., by fusing with an immortalizing cell line such as a myeloma or by manipulating such B-cells by other techniques to perpetuate a cell line capable of producing a monoclonal heterologous antibody.
    Type: Grant
    Filed: February 14, 1997
    Date of Patent: February 23, 1999
    Assignee: GenPharm International, Inc.
    Inventors: Nils Lonberg, Robert M. Kay
  • Patent number: 5814318
    Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and transgenic non-human animals having inactivated endogenous immunoglobulin genes. In one aspect of the invention, endogenous immunoglobulin genes are suppressed by antisense polynucleotides and/or by antiserum directed against endogenous immunoglobulins. Heterologous antibodies are encoded by immunoglobulin genes not normally found in the genome of that species of non-human animal. In one aspect of the invention, one or more transgenes containing sequences of unrearranged heterologous human immunoglobulin heavy chains are introduced into a non-human animal thereby forming a transgenic animal capable of functionally rearranging transgenic immunoglobulin sequences and producing a repertoire of antibodies of various isotypes encoded by human immunoglobulin genes. Such heterologous human antibodies are produced in B-cells which are thereafter immortalized, e.g.
    Type: Grant
    Filed: July 22, 1993
    Date of Patent: September 29, 1998
    Assignee: GenPharm International Inc.
    Inventors: Nils Lonberg, Robert M. Kay
  • Patent number: 5789650
    Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and transgenic non-human animals having inactivated endogenous immunoglobulin genes. In one aspect of the invention, endogenous immunoglobulin genes are suppressed by antisense polynucleotides and/or by antiserum directed against endogenous immunoglobulins. Heterologous antibodies are encoded by immunoglobulin genes not normally found in the genome of that species of non-human animal. In one aspect of the invention, one or more transgenes containing sequences of unrearranged heterologous human immunoglobulin heavy chains are introduced into a non-human animal thereby forming a transgenic animal capable of functionally rearranging transgenic immunoglobulin sequences and producing a repertoire of antibodies of various isotypes encoded by human immunoglobulin genes. Such heterologous human antibodies are produced in B-cells which are thereafter immortalized, e.g.
    Type: Grant
    Filed: March 18, 1992
    Date of Patent: August 4, 1998
    Assignee: GenPharm International, Inc.
    Inventors: Nils Lonberg, Robert M. Kay
  • Patent number: 5770429
    Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.
    Type: Grant
    Filed: October 10, 1995
    Date of Patent: June 23, 1998
    Assignee: GenPharm International, Inc.
    Inventors: Nils Lonberg, Robert M. Kay
  • Patent number: 5661016
    Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and transgenic non-human animals having inactivated endogenous immunoglobulin genes. In one aspect of the invention, endogenous immunoglobulin genes are suppressed by antisense polynucleotides and/or by antiserum directed against endogenous immunoglobulins. Heterologous antibodies are encoded by immunoglobulin genes not normally found in the genome of that species of non-human animal. In one aspect of the invention, one or more transgenes containing sequences of unrearranged heterologous human immunoglobulin heavy chains are introduced into a non-human animal thereby forming a transgenic animal capable of functionally rearranging transgenic immunoglobulin sequences and producing a repertoire of antibodies of various isotypes encoded by human immunoglobulin genes. Such heterologous human antibodies are produced in B-cells which are thereafter immortalized, e.g.
    Type: Grant
    Filed: April 26, 1993
    Date of Patent: August 26, 1997
    Assignee: GenPharm International Inc.
    Inventors: Nils Lonberg, Robert M. Kay
  • Patent number: 5643763
    Abstract: The present invention provides methods for construction of recombinant Yeast Artificial Chromosomes ("YAC") by homologous recombination between YACs during meiosis. In particular, conditions are provided for the step of mating haploid cells and for the step of spore analysis that increase the frequency of spores containing the desired recombinant YAC. The methods find particular use in constructing recombinant YACs between YACs that are incompatible when co-propagated in a diploid and/or that share homology regions of less than about 50 kilobases. Linking YACs, methods of their construction, and methods of their use are provided that allow facile construction of a YAC containing two or more discontinuous regions of DNA.
    Type: Grant
    Filed: November 4, 1994
    Date of Patent: July 1, 1997
    Assignee: Genpharm International, Inc.
    Inventors: Barbara Dunn, Theodore K. Choi
  • Patent number: 5633425
    Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies, i.e., antibodies encoded by immunoglobulin heavy and light chain genes not normally found in the genome of that species of non-human animal. In one aspect of the invention, transgenes encoding unrearranged heterologous human immunoglobulin heavy and light chains are introduced into a non-human animal thereby forming a transgenic animal capable of producing antibodies encoded by human immunoglobulin genes. Such heterologous human antibodies are produced in B-cells which are thereafter immortalized, e.g., by fusing with an immortalizing cell line such as a myeloma or by manipulating such B-cells by other techniques to perpetuate a cell line capable of producing a monoclonal heterologous antibody.
    Type: Grant
    Filed: February 5, 1992
    Date of Patent: May 27, 1997
    Assignee: GenPharm International, Inc.
    Inventors: Nils Lonberg, Robert M. Kay
  • Patent number: 5625126
    Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.
    Type: Grant
    Filed: December 7, 1994
    Date of Patent: April 29, 1997
    Assignee: GenPharm International, Inc.
    Inventors: Nils Lonberg, Robert M. Kay